about
ASICs as therapeutic targets for migraineNeurovascular contributions to migraine: Moving beyond vasodilationCombined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?Increased asymmetric dimethylarginine and nitric oxide levels in patients with migraineEconomic impact of a triptan Rx-to-OTC switch in six EU countries.Increased serum levels of brain-derived neurotropic factor during migraine attacks: a pilot study.Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraineFrequencies of genetic polymorphisms related to triptans metabolism in chronic migraine.Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan.Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse?Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy.Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache.The use of antidepressants for headache prophylaxis.Emerging treatment for chronic migraine and refractory chronic migraine.Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.Dispute settlement understanding on the use of Botox in chronic migraine.Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats.Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat.The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
P2860
Q27013569-8FD523EF-D9EC-47DA-BE07-97DAD10C9532Q28392631-19FC5388-5BE7-4122-A8A3-4EDFF716E0AEQ33859031-268C39F0-6E4C-49BC-B371-9ADC51D13FE1Q34770955-275C7BD0-7DAB-4B05-B9C5-EC0A38BCDF97Q35075662-A66B27C3-4DA0-492D-8651-13E8DFB6002CQ36261123-709389C2-2F02-4BE8-8C1E-66ACA01C8FF3Q36261128-A69A3CCC-9F6C-4E5C-A928-E2070F6F35FFQ36261201-71D5D2D8-B81C-42FA-9FD7-99CEC403F020Q37685635-10B7603E-8B27-4F59-9D47-4678CA6985CAQ37706619-3110407B-DF32-4FD7-AC84-D5418B0BCF07Q37760087-AB944623-8EE1-49FD-8FB5-412FE3725643Q37818258-A3EB8B38-CAE9-4615-A809-57009E8C93EAQ37855782-1F54FA65-D8F4-43EF-A2A2-DA44AA70D507Q37939360-87FA8513-65F5-44D2-99F5-B5DE62BB0A01Q38031982-FF4D2737-191E-4ACE-8E8D-08C90EFB9FEDQ39963170-591A1734-F877-479F-9D36-B97B8B2AE66EQ42682895-FEF5B636-F4C5-4E7D-AD06-80B60C8ADFBEQ46550880-50BD1BD8-8D2E-4586-B9D8-FC324E09C458Q47587769-9BD749C2-6ED5-482E-9181-9B9AC96CA9D3Q48021540-09BA8EC9-B71A-4E7B-A16F-A7A3EC506EE4
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
New drugs for migraine
@ast
New drugs for migraine
@en
type
label
New drugs for migraine
@ast
New drugs for migraine
@en
prefLabel
New drugs for migraine
@ast
New drugs for migraine
@en
P2860
P50
P1476
New drugs for migraine
@en
P2860
P2888
P304
P356
10.1007/S10194-009-0156-9
P577
2009-10-01T00:00:00Z
2009-12-01T00:00:00Z